Nurocor key facts
- Developer of digital clinical development tools designed for transforming document-based processes into structured data workflows.
- It has raised $7.6M across 5 recorded rounds; the latest was Debt ($460K) in Apr 2025.
- Notable investors include Archer Venture Capital, Recurring Capital Partners, Frontier Venture Capital, Simulations Plus.
- Nurocor has filed 7 Form Ds with the SEC since 2022, most recently May 2025 ($460K sold to 8 investors).
- Status: Privately Held (backing).
- ·Watch Nurocor: the Monday email on marks, rounds and moves
Nurocor funding rounds
5 roundsHow much has Nurocor raised?
Nurocor has raised $7.6 million across 5 recorded rounds since 2023. The largest was a $500,000 seed round in Feb 2025; the most recent was a $460,000 debt round in Apr 2025.
Nurocor has filed 7 Form Ds with the SEC since 2022, most recently in May 2025 ($460,000 sold to 8 investors).
Nurocor investors
4 investors are on record for Nurocor, including Archer Venture Capital, Recurring Capital Partners, Frontier Venture Capital and Simulations Plus. The debt round in Apr 2025 drew 8 investors.
About Nurocor
Developer of digital clinical development tools designed for transforming document-based processes into structured data workflows. The company's platform supports protocol design, standards management, and digital asset governance through microservices and shared services like access control and audit trails, enabling pharmaceutical and life sciences organizations to accelerate study design, improve regulatory readiness, and enhance collaboration across teams.
- Sector
- Healthcare
- HQ
- Austin, TX, United States
- Founded
- 2017
- Employees
- 57
- Website
- nurocor.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Nurocor doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.